Alexis Hofherr

Freiburg, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program.

Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program.

Journal: Biologics : targets & therapy

Published: February 04, 2026

Extra-ciliary role for polycystins in regulation of Ezrin and renal tubular morphology.

Extra-ciliary role for polycystins in regulation of Ezrin and renal tubular morphology.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Deep learning-supported image quantification of epithelial cell shapes and its application to polycystic kidney disease.

Deep learning-supported image quantification of epithelial cell shapes and its application to polycystic kidney disease.

Journal: PLoS computational biology

Published: August 19, 2025

Inhibition of IL-33 in Diabetic Kidney Disease: A Randomized, Placebo-Controlled Phase 2b Trial.

Inhibition of IL-33 in Diabetic Kidney Disease: A Randomized, Placebo-Controlled Phase 2b Trial.

Journal: Journal of the American Society of Nephrology : JASN

Published: July 09, 2025

A Case Study of Model-Informed Drug Development of a Novel PCSK9 Antisense Oligonucleotide. Part 2: Phase 2 to Phase 3.

A Case Study of Model-Informed Drug Development of a Novel PCSK9 Antisense Oligonucleotide. Part 2: Phase 2 to Phase 3.

Journal: CPT: pharmacometrics & systems pharmacology

Published: February 21, 2025

Inhibition of Interleukin-33 to Reduce Glomerular Endothelial Inflammation in Diabetic Kidney Disease.

Inhibition of Interleukin-33 to Reduce Glomerular Endothelial Inflammation in Diabetic Kidney Disease.

Journal: Kidney international reports

Published: February 07, 2024

Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide.

Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide.

Journal: British journal of clinical pharmacology

Published: August 25, 2023

Roxadustat and Oral Iron Absorption in Chinese Patients with Anemia of Chronic Kidney Disease: A Randomized, Open-Label, Phase 4 Study (ALTAI).

Roxadustat and Oral Iron Absorption in Chinese Patients with Anemia of Chronic Kidney Disease: A Randomized, Open-Label, Phase 4 Study (ALTAI).

Journal: Advances in therapy

Published: July 14, 2023

A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II.

A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II.

Journal: CPT: pharmacometrics & systems pharmacology

Published: July 25, 2022

Single Gene Mutations in Pkd1 or Tsc2 Alter Extracellular Vesicle Production and Trafficking.

Single Gene Mutations in Pkd1 or Tsc2 Alter Extracellular Vesicle Production and Trafficking.

Journal: Biology

Published: February 21, 2022

Wildtype heterogeneity contributes to clonal variability in genome edited cells.

Wildtype heterogeneity contributes to clonal variability in genome edited cells.

Journal: Scientific reports

Published: January 17, 2022

Targeting inflammation for the treatment of Diabetic Kidney Disease: a five-compartment mechanistic model.

Targeting inflammation for the treatment of Diabetic Kidney Disease: a five-compartment mechanistic model.

Journal: BMC nephrology

Published: September 06, 2021

Showing 1-12 of 31

Last Updated: 09/26/2026